ZA200300411B - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders. - Google Patents

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.

Info

Publication number: ZA200300411B
Authority: ZA; South Africa
Prior art keywords: treatment; methods; proliferative disorders; cellular proliferative; recognition
Prior art date: 2000-08-10

Application number

ZA200300411A

Other languages

English (en)

Inventor

Matthew C Coffey

Bradley G Thompson

Original Assignee

Oncolytics Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-10

Filing date

2001-07-20

Publication date

2004-01-26

2001-07-20 Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc

2004-01-26 Publication of ZA200300411B publication Critical patent/ZA200300411B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Mycology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)

ZA200300411A 2000-08-10 2001-07-20 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders. ZA200300411B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/636,597 US6565831B1 (en)	1999-02-24	2000-08-10	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

Publications (1)

Publication Number	Publication Date
ZA200300411B true ZA200300411B (en)	2004-01-26

Family

ID=24552555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200300411A ZA200300411B (en)	2000-08-10	2001-07-20	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.

Country Status (15)

Country	Link
US (4)	US6565831B1 (fr)
EP (3)	EP1309334B1 (fr)
JP (1)	JP2004505924A (fr)
AR (1)	AR029839A1 (fr)
AT (1)	ATE422358T1 (fr)
AU (2)	AU7621801A (fr)
BR (1)	BR0113128A (fr)
CA (1)	CA2415750C (fr)
DE (1)	DE60137631D1 (fr)
ES (1)	ES2317921T3 (fr)
IL (2)	IL153846A0 (fr)
MX (2)	MX358055B (fr)
NZ (1)	NZ523509A (fr)
WO (1)	WO2002011742A2 (fr)
ZA (1)	ZA200300411B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6136307A (en) *	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) *	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6565831B1 (en) *	1999-02-24	2003-05-20	Oncolytics Biotech Inc.	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US8197430B1 (en)	1998-05-22	2012-06-12	Biopheresis Technologies, Inc.	Method and system to remove cytokine inhibitor in patients
US6620382B1 (en)	1998-05-22	2003-09-16	Biopheresis Technologies, Llc.	Method and compositions for treatment of cancers
US6379708B1 (en) *	1999-11-20	2002-04-30	Cytologic, Llc	Method for enhancing immune responses in mammals
ATE472733T1 (de) *	2000-11-09	2010-07-15	Oncolytics Biotech Inc	Verfahren zur beurteilung von zellulären proliferativen erkrankungen
AR035227A1 (es) *	2001-02-20	2004-05-05	Oncolytics Biotech Inc	Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
AU2002335667A1 (en) *	2001-08-03	2003-02-17	Board Of Regents, The University Of Texas System	Modified reoviral therapy
US20040115170A1 (en) *	2001-11-30	2004-06-17	Brown Earl Garnet	Oncolytic virus
US7198783B2 (en) *	2002-05-10	2007-04-03	Oncolytics Biotech Inc.	Sensitization of neoplastic cells to radiation therapy with reovirus
US7163678B2 (en) *	2002-11-07	2007-01-16	Oncolytics Biotech Inc.	Reovirus for the treatment of ral-mediated cellular proliferative disorders
US20060204476A1 (en) *	2003-04-25	2006-09-14	Roberts Michael S	Treating hepatocellular carcinomas using therapeutic viruses
US20050019308A1 (en) *	2003-07-07	2005-01-27	Oncolytics Biotech Inc.	Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
WO2005043155A1 (fr)	2003-10-21	2005-05-12	Cedars-Sinai Medical Center	Systeme et methode pour le traitement du cancer, notamment des cancers du systeme nerveux central
US20050137152A1 (en) *	2003-12-19	2005-06-23	Danny Cheung	Reovirus for the prevention of neoplasia
EP1917351A4 (fr) *	2005-08-01	2009-12-16	Univ Technologies Int	Réovirus atténué
US10668119B2 (en)	2005-08-01	2020-06-02	Virocure, Inc.	Attenuated reovirus
US20070065514A1 (en) *	2005-09-22	2007-03-22	Howell Mark D	Method for enhancing immune responses in mammals
AU2011205053B2 (en) *	2006-02-02	2013-02-07	Novartis Ag	Tuberous Sclerosis treatment
AU2007211613C1 (en) *	2006-02-02	2018-01-04	Novartis Ag	Tuberous Sclerosis treatment
CA2640286C (fr) *	2006-02-13	2018-01-02	Oncolytics Biotech Inc.	Utilisation d'immunosuppression locale pour ameliorer une therapie virale oncolytique
US20080075690A1 (en) *	2006-09-22	2008-03-27	Mark Douglas Howell	Method for enhancing immune responses in mammals
CA2678721C (fr)	2007-03-12	2018-02-13	Oncolytics Biotech Inc.	Reovirus ayant des sequences modifiees
US10369171B2 (en)	2007-03-13	2019-08-06	Virocure, Inc.	Attenuated reoviruses for selection of cell populations
TW200909581A (en) *	2007-05-21	2009-03-01	Oncolytics Biotech Inc	Mutant reoviruses and methods of making and using
US20100247622A1 (en) *	2007-10-22	2010-09-30	Oncolytics Biotech Inc.	Treatment regime for proliferative disorders
WO2009135614A2 (fr) *	2008-05-09	2009-11-12	Bayer Schering Pharma Aktiengesellschaft	Utilisation d’un régime viral dans le traitement de maladies
CN102065873A (zh) *	2008-05-27	2011-05-18	昂科利蒂克斯生物科技公司	在溶瘤呼肠孤病毒治疗中消除促炎细胞因子的产生
MX339014B (es) *	2008-05-27	2016-05-09	Oncolytics Biotech Inc	Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
EP2365802B1 (fr)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Microcapsules de rapamycine et l'usage pour le traitement du cancer
US9707285B2 (en)	2009-03-16	2017-07-18	Turnstone Limited Partnership	Vaccination methods
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
MX373096B (es) *	2010-12-02	2020-04-27	Oncolytics Biotech Inc	Formulaciones virales líquidas.
CA2901501C (fr)	2013-02-21	2023-03-07	Children's Hospital Of Eastern Ontario Research Institute Inc.	Composition de vaccin
DK2968281T3 (da)	2013-03-13	2020-11-02	Univ Texas	Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
ES2796950T3 (es)	2013-11-15	2020-11-30	Oncolytics Biotech Inc	Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4108983A (en)	1976-06-01	1978-08-22	The Wistar Institute	Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
CA2045129A1 (fr)	1989-02-01	1990-08-02	Alfred I. Geller	Vecteur de l'herpes simplex type 1
WO1990011765A1 (fr)	1989-04-11	1990-10-18	Board Of Regents, The University Of Texas System	Preparation antitumorale obtenue apres traitement d'un oncolysat
CA2039921A1 (fr)	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
CA2051289C (fr)	1990-09-14	2002-11-26	Robert L. Martuza	Destruction de cellules neoplasiques a l'aide d'un virus
DE69426841T2 (de)	1993-02-16	2001-09-06	Onyx Pharma Inc	Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
US5853716A (en)	1995-07-28	1998-12-29	Yale University	Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en)	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
AU719930B2 (en)	1996-05-31	2000-05-18	Genetic Therapy, Inc.	Prevention of graft-versus-host disease with T-cells including polynucleotides encoding negative selective markers
WO1998008541A1 (fr)	1996-08-30	1998-03-05	Genzyme Corporation	Inhibition de la reaction immunitaire primaire et/ou secondaire a l'administration repetee d'un vecteur adenoviral au moyen d'anticorps specifiques de cd40l
US6110461A (en)	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6136307A (en) *	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) *	1999-02-24	2003-05-20	Oncolytics Biotech Inc.	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CA2305269C (fr)	1997-10-09	2012-07-03	Pro-Virus, Inc.	Traitement de neoplasmes par des virus
US6406861B1 (en)	1998-10-07	2002-06-18	Cell Genesys, Inc.	Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6464976B1 (en)	1999-09-07	2002-10-15	Canji, Inc.	Methods and compositions for reducing immune response
US7198783B2 (en) *	2002-05-10	2007-04-03	Oncolytics Biotech Inc.	Sensitization of neoplastic cells to radiation therapy with reovirus

2000
- 2000-08-10 US US09/636,597 patent/US6565831B1/en not_active Expired - Lifetime
2001
- 2001-07-17 AR ARP010103413A patent/AR029839A1/es unknown
- 2001-07-20 JP JP2002517077A patent/JP2004505924A/ja active Pending
- 2001-07-20 BR BR0113128-1A patent/BR0113128A/pt not_active IP Right Cessation
- 2001-07-20 AT AT01953727T patent/ATE422358T1/de not_active IP Right Cessation
- 2001-07-20 DE DE60137631T patent/DE60137631D1/de not_active Expired - Lifetime
- 2001-07-20 NZ NZ523509A patent/NZ523509A/en unknown
- 2001-07-20 ES ES01953727T patent/ES2317921T3/es not_active Expired - Lifetime
- 2001-07-20 CA CA002415750A patent/CA2415750C/fr not_active Expired - Lifetime
- 2001-07-20 EP EP01953727A patent/EP1309334B1/fr not_active Expired - Lifetime
- 2001-07-20 AU AU7621801A patent/AU7621801A/xx active Pending
- 2001-07-20 MX MX2014008295A patent/MX358055B/es unknown
- 2001-07-20 AU AU2001276218A patent/AU2001276218B8/en not_active Expired
- 2001-07-20 ZA ZA200300411A patent/ZA200300411B/xx unknown
- 2001-07-20 EP EP08006359A patent/EP2027866A1/fr not_active Withdrawn
- 2001-07-20 EP EP08006362A patent/EP2016948A3/fr not_active Withdrawn
- 2001-07-20 MX MXPA03000859A patent/MXPA03000859A/es active IP Right Grant
- 2001-07-20 WO PCT/CA2001/001055 patent/WO2002011742A2/fr not_active Ceased
- 2001-07-20 IL IL15384601A patent/IL153846A0/xx unknown
2003
- 2003-01-08 IL IL153846A patent/IL153846A/en active IP Right Grant
- 2003-03-28 US US10/401,032 patent/US7014847B2/en not_active Expired - Fee Related
2005
- 2005-10-21 US US11/255,849 patent/US7452723B2/en not_active Expired - Fee Related
2007
- 2007-05-30 US US11/809,195 patent/US7708987B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1309334B1 (fr)	2009-02-11
ES2317921T3 (es)	2009-05-01
EP2016948A3 (fr)	2009-01-28
DE60137631D1 (de)	2009-03-26
WO2002011742A3 (fr)	2002-04-18
MX358055B (es)	2018-08-03
US6565831B1 (en)	2003-05-20
ATE422358T1 (de)	2009-02-15
EP2027866A1 (fr)	2009-02-25
US7708987B2 (en)	2010-05-04
MXPA03000859A (es)	2004-04-05
IL153846A0 (en)	2003-07-31
EP1309334A2 (fr)	2003-05-14
CA2415750C (fr)	2006-03-28
US20060073166A1 (en)	2006-04-06
US20080075729A1 (en)	2008-03-27
US7452723B2 (en)	2008-11-18
US7014847B2 (en)	2006-03-21
BR0113128A (pt)	2003-07-22
NZ523509A (en)	2004-11-26
CA2415750A1 (fr)	2002-02-14
IL153846A (en)	2010-12-30
AU2001276218B2 (en)	2006-08-03
AU7621801A (en)	2002-02-18
US20030215443A1 (en)	2003-11-20
JP2004505924A (ja)	2004-02-26
AR029839A1 (es)	2003-07-16
AU2001276218B8 (en)	2006-08-24
WO2002011742A2 (fr)	2002-02-14
EP2016948A2 (fr)	2009-01-21

Publication	Publication Date	Title
ZA200300411B (en)	2004-01-26	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
IL144043A0 (en)	2002-04-21	Reovirus for the treatment of cellular proliferative disorders
MXPA03007960A (es)	2003-12-04	Compuestos y metodos para el tratamiento de desordenes urogenitales.
PL362690A1 (en)	2004-11-02	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
IL164533A0 (en)	2005-12-18	Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
AP2006003525A0 (en)	2006-02-28	Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
AU2001285159A1 (en)	2002-05-06	Methods for treating endocrine disorders
WO2003082208A8 (fr)	2005-03-24	Composes de pyrrolopyridazine et methodes d'utilisation de ces composes pour le traitement de maladies proliferatives
IL154881A0 (en)	2003-10-31	Methods for the treatment of cellular proliferative disorders
MXPA03000905A (es)	2003-06-24	Compuestos de poliamina ciclicos como tratamiento contra el cancer.
WO2005030144A3 (fr)	2005-10-27	Composes de pyrrolopyridazine, et procedes pour les utiliser pour traiter des troubles de proliferation
MXPA03003632A (es)	2003-09-10	Metodo para tratamiento de tumores usando terapia de combinacion.
ZA200205191B (en)	2003-07-28	LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
EP1442062A4 (fr)	2005-11-09	Methodes de traitement du carcinome
GC0000155A (en)	2005-06-29	6-Hydroxy-indazole derivatives for treating glaucoma.
MXPA01001535A (es)	2003-08-20	Dispositivo para irradiacion untravioleta para el tratamiento de aguas residuales.
MXPA03001717A (es)	2003-09-22	METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
ZA200307731B (en)	2004-09-13	Use of selective COX-2inhibitors for the treatment of urinary incontinence.
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
MXPA02012907A (es)	2003-09-22	Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
AP2004003070A0 (en)	2004-06-30	The method of treating cancer.
IL174426A0 (en)	2006-08-01	Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
MXPA03004017A (es)	2004-02-12	Metodo para el tratamiento de inflamacion.
MXPA03006249A (es)	2003-09-22	Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03004190A (es)	2003-09-22	Tratamiento de trastornos de ansiedad.